The latest plain language summary of publication from Immunotherapy presents results from the VOLTAIRE-RA study looking at how effective and safe the biosimilar drug BI 695501 is in treating people with rheumatoid arthritis.

Read the summary here.

The original article on which this summary is based is called ‘Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study’ and was originally published in the journal Annals of the Rhematic Diseases. The original article can be read here.